Analysis of the clinical characteristics of immune checkpoint inhibitor-related hypophysitis

Analysis of the clinical characteristics of immune checkpoint inhibitor-related hypophysitis

ObjectiveTo analyze the clinical characteristics of immune checkpoint inhibitor (ICI)-related hypophysitis. MethodsA retrospective analysis was conducted on patients diagnosed with ICI-related hypophysitis and treated at the Department of Endocrinology, The First Affiliated Hospital with Nanjing Med...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhixiao WANG, Yun SHI, Min SUN, Xuqin ZHENG, Tao YANG, Min SHEN
Format:	Article
Language:	English
Published:	Shanghai Chinese Clinical Medicine Press Co., Ltd. 2025-08-01
Series:	Zhongguo Linchuang Yixue
Subjects:	immune checkpoint inhibitor immune-related adverse event hypophysitis clinical characteristic
Online Access:	https://www.c-jcm.com/article/doi/10.12025/j.issn.1008-6358.2025.20250397
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical characteristic analysis of immune checkpoint inhibitor-related pituitary adverse events
by: Yufan ZHENG, et al.
Published: (2025-08-01)

Retrospective analysis of clinical characteristics and treatment of patients with immune checkpoint inhibitors-induced adrenal insufficiency
by: Xiao Huang, et al.
Published: (2025-08-01)

Application of Immune Checkpoint Inhibitors in Cancer
by: Zhijun Chen, et al.
Published: (2025-08-01)

Endocrine adverse events of immune checkpoint inhibitors: results of a single-center study
by: E. V. Poddubskaya, et al.
Published: (2019-12-01)

Hepatotoxicity induced by immune checkpoint inhibitors
by: Flaviu Muresan, et al.
Published: (2024-10-01)

Adverse reactions of immune checkpoint inhibitors
by: E. R. Zagidullina, et al.
Published: (2025-06-01)

Can Janus kinase inhibitors be used to treat immune checkpoint inhibitor associated adverse events?
by: Jürgen Braun, et al.
Published: (2024-11-01)

Immune Checkpoint Inhibitor‐Related Dysautonomia in Merkel Cell Carcinoma: A Case Report
by: Nidhi Kuchimanchi, et al.
Published: (2025-07-01)

Investigating Immune Checkpoint Inhibitor-Induced Pancreatic Injury: When to Discontinue Cancer Therapy
by: Enrico Celestino Nista, et al.
Published: (2025-06-01)

Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy
by: Aya F. Ozaki, et al.
Published: (2025-03-01)

Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER
by: Xiaomeng Di, et al.
Published: (2025-07-01)

Neuroimaging features of immune-related adverse events due to immune checkpoint inhibitor therapy
by: Arian Lasocki, et al.
Published: (2025-06-01)

Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study
by: Jonas Paul Wiegmann, et al.
Published: (2025-02-01)

Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors
by: Nora Möhn, et al.
Published: (2025-12-01)

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)
by: M. Yu. Fedyanin, et al.
Published: (2023-06-01)

Development of a Predictive Model for Classifying Immune Checkpoint Inhibitor‐Induced Liver Injury Types
by: Jun Kitadai, et al.
Published: (2025-04-01)

Clinical features and risk factors of immune-mediated liver injury in non-small cell lung cancer patients treated with immune checkpoint inhibitors
by: Ling Yang, et al.
Published: (2025-08-01)

Immune checkpoint inhibitor-associated diabetes mellitus: the case series report
by: Yuhong Ma, et al.
Published: (2025-07-01)

Adrenal insufficiency induced by immune checkpoint inhibitors anticancer therapy
by: Paulina Ramaneckaite, et al.
Published: (2025-01-01)

Reporting of immune-related adverse events in US Food and Drug Administration approvals of immune checkpoint inhibitors
by: Shaili Tapiavala, et al.
Published: (2025-08-01)

Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy
by: Tatsushi Kawada, et al.
Published: (2025-07-01)

Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment
by: John Storwick, et al.
Published: (2025-07-01)

Immune checkpoint inhibitor-induced myocarditis and multiple adverse events with pre-existing rheumatoid arthritis: a case report and literature review
by: Shion Kachi, et al.
Published: (2025-08-01)

Fatal toxic epidermal necrolysis associated with an immune checkpoint inhibitor
by: Chiaki Seki, et al.
Published: (2025-05-01)

Case Report: Immune checkpoint inhibitor-induced myositis without elevated creatine kinase
by: Klajdi Begaj, et al.
Published: (2025-06-01)

Immune hemolytic anemia associated with the use of immune checkpoint inhibitors: a scoping review
by: Juan-Manuel Hernandez-Martinez, et al.
Published: (2025-07-01)

Construction of predictive model for programmed death-1 inhibitor-related endocrine adverse events
by: Jiaying SHI, et al.
Published: (2025-08-01)

Arthropathy associated with antitumor checkpoint inhibitors therapy: current understanding of the problem
by: A. D. Koltakova, et al.
Published: (2023-10-01)

Immune checkpoint inhibitor-related myocarditis during DUO-E regimen for endometrial cancer: The first case report in gynecologic oncology
by: Eri Yamabe, et al.
Published: (2025-10-01)

Baseline profile peripheral Tfh cells predict immune-related adverse events in immune checkpoint inhibitor therapy of gastrointestinal cancer
by: Yifan Wang, et al.
Published: (2025-05-01)

Immune Checkpoint Inhibitors and Cardiovascular Adverse Events
by: Maria Luisa De Perna, et al.
Published: (2025-08-01)

Function of 18F-FDG PET/CT radiomics in the detection of checkpoint inhibitor-induced liver injury (CHILI)
by: Clémence M. C. Huigen, et al.
Published: (2025-08-01)

Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors
by: Anqi Lin, et al.
Published: (2025-06-01)

Fatal acquired coagulation factor V deficiency after hepatectomy for advanced hepatocellular carcinoma as a possible immune checkpoint inhibitor-related adverse event: a case report
by: Shintaro Arakaki, et al.
Published: (2023-02-01)

Case Report: Immune-related eruptive keratoacanthoma with fungal coinfection under PD-1 inhibitor therapy: a diagnostic and therapeutic challenge
by: Ying-Jie Su, et al.
Published: (2025-08-01)

Safety and clinical efficacy of immune checkpoint inhibitors in pediatric hepatocellular carcinoma: a case report and review of the literature
by: Xiaoting Zhong, et al.
Published: (2025-08-01)

Cardiotoxicity mechanisms of antitumor therapy with immune checkpoint inhibitors: new achievements
by: L. D. Khidirova, et al.
Published: (2024-06-01)

IgG4-related disease with interstitial nephritis in a patient with metastatic melanoma following immune checkpoint inhibitor treatment: a case report
by: Thabuna Sivaprakasam, et al.
Published: (2025-08-01)

Successful management of chronic eosinophilic pneumonia triggered by immune checkpoint inhibitor: a case report and literature review
by: Yasuhito Suzuki, et al.
Published: (2025-07-01)

Correlation between different levels of thyroid autoantibodies and immune checkpoint inhibitor-associated thyroid dysfunction
by: Yanyan Jiao, et al.
Published: (2025-08-01)